NCT03116906View on ClinicalTrials.gov

Safety and Tolerability of BI 685509 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 24, 2017

Primary Completion Date

June 1, 2018

Study Completion Date

June 1, 2018

Conditions
Healthy
Interventions
DRUG

BI 685509

to be given for a total of up to 15 days

DRUG

Placebo

to be given for a total of up to 15 days

Trial Locations (1)

68167

CRS Clinical Research Services Mannheim GmbH, Mannheim

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT03116906 - Safety and Tolerability of BI 685509 in Healthy Subjects | Biotech Hunter | Biotech Hunter